SanBio Company Limited EBIT

The latest EBIT for 4592.T is $-3.7B as of July 2026. That compares with $-3.8B in the prior-year period — up 3.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside SanBio Company Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4592.T's EBIT moved from $-3.8B to $-3.7B — a 3.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SanBio Company Limited's operating scale or balance-sheet position.

Against Healthcare companies, 4592.T currently prints $-3.7B for EBIT, while the sector average sits near $110B. That is roughly 103.4% below the sector mean. Large gaps often invite a closer look at SanBio Company Limited's growth, margins, and balance sheet.

A EBIT figure of $-3.7B for 4592.T is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 4592.T's EBIT ($-3.7B), review year-over-year change from $-3.8B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.